Prevalencia de anticuerpos anti HLA y/o HNA en muestras de donantes de sangre: una revisión sistemática

dc.contributor.advisorCamacho Rodriguez, Bernado Armandospa
dc.contributor.advisorVallejo Ortega, María Teresaspa
dc.contributor.advisorHenao Riveros, Sandra Consuelospa
dc.contributor.authorAngel Peña, Verónicaspa
dc.date.accessioned2024-07-29T20:18:06Z
dc.date.available2024-07-29T20:18:06Z
dc.date.issued2024-01
dc.descriptionilustraciones, diagramasspa
dc.description.abstractIntroducción: Los anticuerpos anti-HLA y anti-HNA se encuentran dirigidos contra antígenos que se encuentran en los leucocitos y otras células (los antígenos HNA se encuentran sobre los neutrófilos, y los antígenos HLA sobre la mayoría de células nucleadas). Se han descrito dos sistemas de antígenos leucocitarios: el sistema HLA y el sistema HNA; si bien son bastante diferentes, están asociados por causar TRALI, una condición asociada a la transfusión de componentes sanguíneos que contienen estos anticuerpos, y que puede llegar a comprometer la vida del paciente. Se realizó una revisión sistemática para establecer la frecuencia de estos anticuerpos en donantes de sangre. Objetivo: Determinar la prevalencia de prueba positiva para anticuerpos anti-HLA y anti-HNA en muestras de donantes de sangre Métodos de búsqueda: Se realizó una búsqueda sistemática en las bases de datos electrónicas MEDLINE, EMBASE y LILACS para detectar estudios observacionales o experimentales que hayan medido la prevalencia de anticuerpos anti-HLA, anti-HNA o ambos en muestras de donantes de sangre, ensayos clínicos que compararon la capacidad de pruebas de detección de los anticuerpos y estudios de pruebas diagnósticas que evaluaron la exactitud de las pruebas usadas. Luego de la extracción y calificación por dos investigadores, se evaluó la heterogeneidad y se generaron estimadores de resumen mediante metaanálisis de proporciones por método directo. Resultados principales: Como resultados de la búsqueda fueron detectadas 3340 referencias, luego del proceso de selección fueron incluidos un total de 23 estudios; de los cuales 22 hicieron detección de anticuerpos anti-HLA total y 12 hicieron detección de anticuerpos anti-HNA. Se reportaron los rangos de prevalencias para anticuerpos anti-HLA mediante síntesis textual narrativa debido a que se obtuvieron valores de I2 mayores al 70%. La prevalencia resumida de HNA total fue del 1%. Conclusiones: Existe una alta incertidumbre sobre la magnitud de la prevalencia de anticuerpos anti-HLA y anti-HNA en donantes de bancos de sangre. Podría haber una mayor prevalencia de anticuerpos en mujeres con más de una gestación, pero se requieren estudios que precisen otros factores que puedan mejorar la certeza de la prevalencia de anticuerpos en esta población y expliquen la alta heterogeneidad encontrada. Se necesitan investigaciones adicionales permitan estimar el efecto de los eventos sensibilizantes con la prevalencia de anticuerpos anti-HLA y anti-HNA en donantes de sangre. (Texto tomado de la fuente).spa
dc.description.abstractIntroduction: Anti-HLA and anti-HNA antibodies are directed against antigens found on leukocytes and other cells (HNA antigens are found on neutrophils, and HLA antigens on most nucleated cells). Two leukocyte antigen systems have been described: the HLA system and the HNA system; Although they are quite different, they are associated with causing TRALI, a condition associated with the transfusion of blood components that contain these antibodies, and which can compromise the patient's life. A systematic review was performed to establish the frequency of these antibodies in blood donors. Objective: Determine the prevalence of positive tests for anti-HLA and anti-HNA antibodies in blood donor samples. Search methods: A systematic search was performed in the electronic databases MEDLINE, EMBASE and LILACS to detect observational or experimental studies that have measured the prevalence of anti-HLA antibodies, anti-HNA antibodies or both in blood donor samples, assays clinical trials that compared the ability of antibody detection tests and diagnostic testing studies that evaluated the accuracy of the tests used. After extraction and scoring by two researchers, heterogeneity was assessed and summary estimators were generated through meta-analysis of proportions by direct method. Results: As results of the search, 3340 references were detected, after the selection process a total of 23 studies were included; of which 22 detected total anti-HLA antibodies and 12 detected anti-HNA antibodies. The prevalence ranges for anti-HLA antibodies were reported through narrative textual synthesis because I2 values ​​greater than 70% were obtained. The summary prevalence of total HNA was 1%. Conclusions: There is high uncertainty about the magnitude of the prevalence of anti-HLA and anti-HNA antibodies in blood bank donors. There could be a higher prevalence of antibodies in women with more than one pregnancy, but studies are required that specify other factors that can improve the certainty of the prevalence of antibodies in this population and explain the high heterogeneity found. Additional research is needed to estimate the effect of sensitizing events on the prevalence of anti-HLA and anti-HNA antibodies in blood donors.eng
dc.description.degreelevelMaestríaspa
dc.description.degreenameMagíster en Inmunologíaspa
dc.format.extentxiii, 75 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameUniversidad Nacional de Colombiaspa
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombiaspa
dc.identifier.repourlhttps://repositorio.unal.edu.co/spa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/86647
dc.language.isospaspa
dc.publisherUniversidad Nacional de Colombiaspa
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotáspa
dc.publisher.facultyFacultad de Medicinaspa
dc.publisher.placeBogotá, Colombiaspa
dc.publisher.programBogotá - Medicina - Maestría en Inmunologíaspa
dc.relation.indexedBiremespa
dc.relation.referencesTung JP, Chiaretti S, Dean MM, Sultana AJ, Reade MC, Fung YL. Transfusion-related acute lung injury (TRALI): Potential pathways of development, strategies for prevention and treatment, and future research directions. Blood Rev. 2022;53:100926spa
dc.relation.referencesBarnard RD. Indiscriminate transfusion: a critique of case reports illustrating hypersensitivity reactions. N Y State J Med. 1951;51(20):2399-402spa
dc.relation.referencesPopovsky MA, Abel MD, Moore SB. Transfusion-related acute lung injury associated with passive transfer of antileukocyte antibodies. Am Rev Respir Dis. 1983;128(1):185-9spa
dc.relation.referencesPopovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion. 1985;25(6):573-7spa
dc.relation.referencesKleinman S, Caulfield T, Chan P, Davenport R, McFarland J, McPhedran S, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion. 2004;44(12):1774-89spa
dc.relation.referencesVlaar APJ, Toy P, Fung M, Looney MR, Juffermans NP, Bux J, et al. A consensus redefinition of transfusion-related acute lung injury. Transfusion. 2019;59(7):2465-76spa
dc.relation.referencesOtrock ZK, Liu C, Grossman BJ. Transfusion-related acute lung injury risk mitigation: an update. Vox Sang. 2017;112(8):694-703spa
dc.relation.referencesToy P, Kleinman SH, Looney MR. Proposed revised nomenclature for transfusion-related acute lung injury. Transfusion. 2017;57(3):709-13spa
dc.relation.referencesSweeney RM, McAuley DF. Acute respiratory distress syndrome. Lancet. 2016;388(10058):2416-30spa
dc.relation.referencesSilliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood. 2005;105(6):2266-73spa
dc.relation.referencesChapman CE, Stainsby D, Jones H, Love E, Massey E, Win N, et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion. 2009;49(3):440-52spa
dc.relation.referencesAndreu G, Boudjedir K, Muller JY, Pouchol E, Ozier Y, Fevre G, et al. Analysis of Transfusion-Related Acute Lung Injury and Possible Transfusion-Related Acute Lung Injury Reported to the French Hemovigilance Network From 2007 to 2013. Transfus Med Rev. 2018;32(1):16-27spa
dc.relation.referencesKopko PM, Popovsky MA, MacKenzie MR, Paglieroni TG, Muto KN, Holland PV. HLA class II antibodies in transfusion-related acute lung injury. Transfusion. 2001;41(10):1244-8spa
dc.relation.referencesSilliman CC, Voelkel NF, Allard JD, Elzi DJ, Tuder RM, Johnson JL, et al. Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. J Clin Invest. 1998;101(7):1458-67spa
dc.relation.referencesPeters AL, van Hezel ME, Juffermans NP, Vlaar AP. Pathogenesis of non-antibody mediated transfusion-related acute lung injury from bench to bedside. Blood Rev. 2015;29(1):51-61spa
dc.relation.referencesVlaar AP, Juffermans NP. Transfusion-related acute lung injury: a clinical review. Lancet. 2013;382(9896):984-94spa
dc.relation.referencesToy P, Gajic O, Bacchetti P, Looney MR, Gropper MA, Hubmayr R, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood. 2012;119(7):1757-67spa
dc.relation.referencesWyman TH, Bjornsen AJ, Elzi DJ, Smith CW, England KM, Kelher M, et al. A two-insult in vitro model of PMN-mediated pulmonary endothelial damage: requirements for adherence and chemokine release. Am J Physiol Cell Physiol. 2002;283(6):C1592-603spa
dc.relation.referencesVlaar AP, Kuipers MT, Hofstra JJ, Wolthuis EK, Wieland CW, Roelofs JJ, et al. Mechanical ventilation and the titer of antibodies as risk factors for the development of transfusion-related lung injury. Crit Care Res Pract. 2012;2012:720950spa
dc.relation.referencesRana R, Fernández-Pérez ER, Khan SA, Rana S, Winters JL, Lesnick TG, et al. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. Transfusion. 2006;46(9):1478-83spa
dc.relation.referencesGajic O, Rana R, Winters JL, Yilmaz M, Mendez JL, Rickman OB, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med. 2007;176(9):886-91spa
dc.relation.referencesVlaar AP, Binnekade JM, Prins D, van Stein D, Hofstra JJ, Schultz MJ, et al. Risk factors and outcome of transfusion-related acute lung injury in the critically ill: a nested case-control study. Crit Care Med. 2010;38(3):771-8spa
dc.relation.referencesPeters AL, Van Stein D, Vlaar AP. Antibody-mediated transfusion-related acute lung injury; from discovery to prevention. Br J Haematol. 2015;170(5):597-614spa
dc.relation.referencesMorsing KSH, Peters AL, van Buul JD, Vlaar APJ. The role of endothelium in the onset of antibody-mediated TRALI. Blood Rev. 2018;32(1):1-7spa
dc.relation.referencesLooney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest. 2009;119(11):3450-61spa
dc.relation.referencesKapur R, Kim M, Aslam R, McVey MJ, Tabuchi A, Luo A, et al. T regulatory cells and dendritic cells protect against transfusion-related acute lung injury via IL-10. Blood. 2017;129(18):2557-69spa
dc.relation.referencesLooney MR, Su X, Van Ziffle JA, Lowell CA, Matthay MA. Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury. J Clin Invest. 2006;116(6):1615-23spa
dc.relation.referencesKelher MR, Banerjee A, Gamboni F, Anderson C, Silliman CC. Antibodies to major histocompatibility complex class II antigens directly prime neutrophils and cause acute lung injury in a two-event in vivo rat model. Transfusion. 2016;56(12):3004-11spa
dc.relation.referencesThomas GM, Carbo C, Curtis BR, Martinod K, Mazo IB, Schatzberg D, et al. Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. Blood. 2012;119(26):6335-43spa
dc.relation.referencesBux J, Sachs UJ. The pathogenesis of transfusion-related acute lung injury (TRALI). Br J Haematol. 2007;136(6):788-99spa
dc.relation.referencesBux J. Antibody-mediated (immune) transfusion-related acute lung injury. Vox Sang. 2011;100(1):122-8spa
dc.relation.referencesStroncek DF, Fadeyi E, Adams S. Leukocyte antigen and antibody detection assays: tools for assessing and preventing pulmonary transfusion reactions. Transfus Med Rev. 2007;21(4):273-86spa
dc.relation.referencesDelbos F, Cesbron A. [Caracterization of HLA allo-immunization and clinical impact in transfusion and organ transplantation]. Transfus Clin Biol. 2017;24(3):131-7spa
dc.relation.referencesMorsing KSH, Peters AL, van Buul JD, Vlaar APJ. The role of endothelium in the onset of antibody-mediated TRALI. Blood Reviews. 2018;32(1):1-7spa
dc.relation.referencesSachs UJ, Wasel W, Bayat B, Bohle RM, Hattar K, Berghöfer H, et al. Mechanism of transfusion-related acute lung injury induced by HLA class II antibodies. Blood. 2011;117(2):669-77spa
dc.relation.referencesSeeger W, Schneider U, Kreusler B, von Witzleben E, Walmrath D, Grimminger F, et al. Reproduction of transfusion-related acute lung injury in an ex vivo lung model. Blood. 1990;76(7):1438-44spa
dc.relation.referencesMartínez Álvarez JC. [Antibodies, human leukocyte antigens, and biomodulators in transfusion-related acute adverse effects]. Gac Med Mex. 2013;149(1):81-8spa
dc.relation.referencesBrowne T, Dearman RJ, Poles A. Human neutrophil antigens: Nature, clinical significance and detection. Int J Immunogenet. 2021;48(2):145-56spa
dc.relation.referencesMoritz E, Norcia AM, Cardone JD, Kuwano ST, Chiba AK, Yamamoto M, et al. Human neutrophil alloantigens systems. An Acad Bras Cienc. 2009;81(3):559-69spa
dc.relation.referencesFlesch BK, Reil A. Molecular Genetics of the Human Neutrophil Antigens. Transfus Med Hemother. 2018;45(5):300-9spa
dc.relation.referencesAABB. Association Bulletin #14-02. 1402. EEUU2014. p. 14spa
dc.relation.referencesAssociation Bulletin #14-02, (2014)spa
dc.relation.referencesMaria B, Michel G. Informe de actividad transfusional, Colombia 2022. 2023spa
dc.relation.referencesPeñuela O, Beltrán M, Rebollo S, Bermúdez M. Manual de hemovigilancia. Bogotá, Colombia2010spa
dc.relation.referencesMichel G, Andrea H, María B. CASO 3-2021: NOTIFICACIÓN DE MORTALIDAD SECUNDARIA A REACCIÓN ADVERSA A LA TRANSFUSIÓN POR ADMINISTRACIÓN DE HEMOCOMPONENTE ABO INCOMPATIBLE. Bogotá2022spa
dc.relation.referencesDecreto 1571 de 1993, (1993)spa
dc.relation.referencesCross AR. What is a Blood Bank? https://www.redcrossblood.org/local-homepage/news/article/blood-banks-defined.html [Available from: https://www.redcrossblood.org/local-homepage/news/article/blood-banks-defined.htmlspa
dc.relation.referencesHematology ASo. Blood Banking and Donation https://www.hematology.org/education/patients/blood-basics/blood-banking-and-donation2021 [Available from: https://www.hematology.org/education/patients/blood-basics/blood-banking-and-donationspa
dc.relation.referencesAl MPe. Quality asssessment tool for cross sectional studies: Newcastle-Otawa Scale. 2016spa
dc.relation.referencesLipsey M, Wilson D. Practical Meta-Analysis <p class="EndNoteBibliography" style="margin-top:0cm;margin-right:0cm;margin-bottom: 0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt">. 1 ed. California2001spa
dc.relation.referencesDeeks J, Higgins J, Altman D. Analysing data and undertaking meta-analyses. In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions (Version 510 ed). London: The Cochrane Collaboration; 2011spa
dc.relation.referencesBoulton-Jones R, Norris A, O'Sullivan A, Comrie A, Forgan M, Rawlinson PS, et al. The impact of screening a platelet donor panel for human leucocyte antigen antibodies to reduce the risk of transfusion-related acute lung injury. Transfus Med. 2003;13(3):169-70spa
dc.relation.referencesBray RA, Harris SB, Josephson CD, Hillyer CD, Gebel HM. Unappreciated risk factors for transplant patients: HLA antibodies in blood components. Hum Immunol. 2004;65(3):240-4spa
dc.relation.referencesCarrick DM, Johnson B, Kleinman SH, Vorhaben R, Chance SC, Lee JH, et al. Agreement among HLA antibody detection assays is higher in ever-pregnant donors and improved using a consensus cutoff. Transfusion. 2011;51(5):1105-16spa
dc.relation.referencesDe Clippel D, Baeten M, Torfs A, Emonds MP, Feys HB, Compernolle V, et al. Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy. Transfusion. 2014;54(12):3036-42spa
dc.relation.referencesDensmore TL, Goodnough LT, Ali S, Dynis M, Chaplin H. Prevalence of HLA sensitization in female apheresis donors. Transfusion. 1999;39(1):103-6spa
dc.relation.referencesDunbar NM, Yazer MH, Bravo MD, Kamel HT, Gorlin J, Norris PJ, et al. An association between ABO group and HLA antibody detection. Transfusion. 2017;57(2):313-8spa
dc.relation.referencesFadeyi E, Adams S, Peterson B, Hackett J, Byrne P, Klein HG, et al. Analysis of a high-throughput HLA antibody screening assay for use with platelet donors. Transfusion. 2008;48(6):1174-9spa
dc.relation.referencesGottschall JL, Triulzi DJ, Curtis B, Kakaiya RM, Busch MP, Norris PJ, et al. The frequency and specificity of human neutrophil antigen antibodies in a blood donor population. Transfusion. 2011;51(4):820-7spa
dc.relation.referencesHernández H, Romero A. FRECUENCIA DE ANTICUERPOS ANTI - HLA DE CLASE I EN DODNATES MULTIPARAS DE PLAQUETAS POR AFERESIS Y SANGRE TOTAL DEL BANCO NACIONAL DE SANGRE DE LA CRUZ ROJA COLOMBIANA: Pontificia Universidad Javeriana; 2011spa
dc.relation.referencesInsunza A, Romon I, Gonzalez-Ponte ML, Hoyos A, Pastor JM, Iriondo A, et al. Implementation of a strategy to prevent TRALI in a regional blood centre. Transfus Med. 2004;14(2):157-64spa
dc.relation.referencesKakaiya RM, Triulzi DJ, Wright DJ, Steele WR, Kleinman SH, Busch MP, et al. Prevalence of HLA antibodies in remotely transfused or alloexposed volunteer blood donors. Transfusion. 2010;50(6):1328-34spa
dc.relation.referencesLucas G, Win N, Calvert A, Green A, Griffin E, Bendukidze N, et al. Reducing the incidence of TRALI in the UK: the results of screening for donor leucocyte antibodies and the development of national guidelines. Vox Sang. 2012;103(1):10-7spa
dc.relation.referencesNguyen XD, Dengler T, Schulz-Linkholt M, Klüter H. A novel tool for high-throughput screening of granulocyte-specific antibodies using the automated flow cytometric granulocyte immunofluorescence test (Flow-GIFT). ScientificWorldJournal. 2011;11:302-9spa
dc.relation.referencesNguyen XD, Schulze TJ, Bugert P, Lauber-Härtl S, Schulz-Linkholt M, González-Schulze K, et al. Granulocyte antibodies in male blood donors: can they trigger transfusion-related acute lung injury? Transfusion. 2018;58(8):1894-901spa
dc.relation.referencesNowosiad-Magda M, Myślak M, Roszkowska P, Borowiec-Chłopek Z, Krasnodębska-Szponder B, Kłosińska E, et al. Anti-human leukocyte antigen antibodies are present in blood of blood donors: is therapy with blood preparations safe for graft recipients? Transplant Proc. 2014;46(8):2565-71spa
dc.relation.referencesPorretti L, Cattaneo A, Coluccio E, Mantione E, Colombo F, Mariani M, et al. Implementation and outcomes of a transfusion-related acute lung injury surveillance programme and study of HLA/HNA alloimmunisation in blood donors. Blood Transfus. 2012;10(3):351-9spa
dc.relation.referencesPowers A, Stowell CP, Dzik WH, Saidman SL, Lee H, Makar RS. Testing only donors with a prior history of pregnancy or transfusion is a logical and cost-effective transfusion-related acute lung injury prevention strategy. Transfusion. 2008;48(12):2549-58spa
dc.relation.referencesPriyadarsini AJ, Dhawan HK, Sharma RR, Saikia B, Minz RW. Prevalance of Anti-HLA antibodies in parous female blood donors: A pilot study from tertiary care hospital of North India. Asian J Transfus Sci. 2021;15(1):16-20spa
dc.relation.referencesQuillen K, Medrano C, Adams S, Peterson B, Hackett J, Leitman SF, et al. Screening plateletpheresis donors for HLA antibodies on two high-throughput platforms and correlation with recipient outcome. Transfusion. 2011;51(3):504-10spa
dc.relation.referencesReil A, Keller-Stanislawski B, Günay S, Bux J. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang. 2008;95(4):313-7spa
dc.relation.referencesSachs UJ, Link E, Hofmann C, Wasel W, Bein G. Screening of multiparous women to avoid transfusion-related acute lung injury: a single centre experience. Transfus Med. 2008;18(6):348-54spa
dc.relation.referencesSchönbacher M, Aichinger N, Weidner L, Jungbauer C, Grabmer C, Schuha B, et al. Leukocyte-Reactive Antibodies in Female Blood Donors: The Austrian Experience. Transfus Med Hemother. 2021;48(2):99-108spa
dc.relation.referencesSigle JP, Thierbach J, Infanti L, Muriset M, Hunziker G, Chassot K, et al. Anti-leucocyte antibodies in platelet apheresis donors with and without prior immunizing events: implications for TRALI prevention. Vox Sang. 2013;105(3):244-52spa
dc.relation.referencesSimtong P, Sudwilai Y, Cheunta S, Leelayuwat C, Romphruk AV. Prevalence of leucocyte antibodies in non-transfused male and female platelet apheresis donors. Transfus Med. 2021;31(3):186-92spa
dc.relation.referencesTriulzi DJ, Kleinman S, Kakaiya RM, Busch MP, Norris PJ, Steele WR, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion. 2009;49(9):1825-35spa
dc.relation.referencesXia W, Ye X, Xu X, Chen D, Deng J, Chen Y, et al. The prevalence of leucocyte alloantibodies in blood donors from South China. Transfus Med. 2015;25(6):385-92spa
dc.relation.referencesEndres RO, Kleinman SH, Carrick DM, Steele WR, Wright DJ, Norris PJ, et al. Identification of specificities of antibodies against human leukocyte antigens in blood donors. Transfusion. 2010;50(8):1749-60spa
dc.relation.referencesMaślanka K, Michur H, Zupańska B, Uhrynowska M, Nowak J. Leucocyte antibodies in blood donors and a look back on recipients of their blood components. Vox Sang. 2007;92(3):247-9spa
dc.relation.referencesMiddelburg RA, Porcelijn L, Lardy N, Briët E, Vrielink H. Prevalence of leucocyte antibodies in the Dutch donor population. Vox Sang. 2011;100(3):327-35spa
dc.relation.referencesBray RA, Nickerson PW, Kerman RH, Gebel HM. Evolution of HLA antibody detection: technology emulating biology. Immunol Res. 2004;29(1-3):41-54spa
dc.relation.referencesNakamura J, Nakajima F, Kamada H, Tadokoro K, Nagai T, Satake M. Males without apparent alloimmunization could have HLA antibodies that recognize target HLA specificities expressed on cells. HLA. 2017;89(5):285-92spa
dc.relation.referencesMorales-Buenrostro LE, Terasaki PI, Marino-Vázquez LA, Lee JH, El-Awar N, Alberú J. "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation. 2008;86(8):1111-5spa
dc.relation.referencesEl-Awar N. HLA epitopes - Empirically defined as conformational amino acids sequences of the HLA antigen and are likely to be part of the binding sites of anti-HLA antibodies. Hum Immunol. 2022;83(3):204-18spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseAtribución-NoComercial 4.0 Internacionalspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/spa
dc.subject.ddc610 - Medicina y salud::612 - Fisiología humanaspa
dc.subject.decsAnticuerposspa
dc.subject.decsAntibodieseng
dc.subject.decsLesión Pulmonar Aguda Postransfusional/inmunologíaspa
dc.subject.decsTransfusion-Related Acute Lung Injury/inmunologyeng
dc.subject.decsDonantes de Sangrespa
dc.subject.decsBlood Donorseng
dc.subject.proposalRevisión sistemáticaspa
dc.subject.proposalAnticuerposspa
dc.subject.proposalAntígeno leucocitario humanospa
dc.subject.proposalAntígeno plaquetario humanospa
dc.subject.proposalLesión pulmonar aguda relacionada con transfusión (TRALI)spa
dc.subject.proposalSystematic revieweng
dc.subject.proposalAntibodieseng
dc.subject.proposalHuman leukocyte antigeneng
dc.subject.proposalHuman platelet antigeneng
dc.subject.proposalTransfusion-related acute lung injury (TRALI)eng
dc.titlePrevalencia de anticuerpos anti HLA y/o HNA en muestras de donantes de sangre: una revisión sistemáticaspa
dc.title.translatedPrevalence of anti HLA and/or HNA antibodies in blood donor samples: a systematic revieweng
dc.typeTrabajo de grado - Maestríaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdccspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TMspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dcterms.audience.professionaldevelopmentEstudiantesspa
dcterms.audience.professionaldevelopmentInvestigadoresspa
dcterms.audience.professionaldevelopmentMaestrosspa
dcterms.audience.professionaldevelopmentPúblico generalspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
53160608.2024.pdf
Tamaño:
1.42 MB
Formato:
Adobe Portable Document Format
Descripción:
Tesis de Maestría en Inmunología

Bloque de licencias

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
license.txt
Tamaño:
5.74 KB
Formato:
Item-specific license agreed upon to submission
Descripción: